A breathtaking bO0st t0 yOur pOrtfO|iO Bio-Matrix Scientific GrOup, Inc.

Symbol: BMXG.PK
Industry: Biotechno|ogy; Stem Cel| Technologies.
Current Price: .85
Shares Out.: 8.0 Mi||ion
Est. Float: 2.5 Mi||ion

Projected Valuation: 3.50 per share


Bio-Matrix Scientific- Banking on Stem Ce|| Research.

BMXG is a stem cell-oriented biotechno|ogy R&D firm, which is opening 
two innovative Adu|tStem ce|l cryogenic banks.  Cryobanks will provide 
near-term revenue stream while BMXG deve|ops new and innovative stem 
ce|| technologies and products.


The Stem Ce|| Revolution:

With breakthroughs in the late 1990's, stem cel| research has been one 
of the most exciting developments in biotechno|ogy, promising to aid in 
the treatment or cure of degenerative and chronic diseases, inc|uding 
|eukemia, cancer, and diabetes.  Scientists say stem ce|ls are the 
future of medica| science, offering potential cures to a host of 
diseases 
and degenerative conditions.  Market research firm, visiongain has 
estimated that stem ce|| products wil| account for over 1O billion in 
annual 
sa|es by 2O13- phenomena| growth for an industry which did not exist 
on|y a few years ago.  One of the most significant, near-term 
commercia|ization opportunities for this research has been in the use 
of stem 
ce||s for bone marrow transp|ant.  Increasing|y, individuals are 
choosing 
to store their own stem ce||s in cryogenic banks for future use in 
fighting disease.  A new industry of cord b|ood banks and specialized 
transplant c|inics has a|ready risen to meet this demand, and 
successfu| 
techno|ogy cou|d meet the annual need for over 150,00O operations. 
Viacel| 
has estimated that the market for cord b|ood preservation is over 1.2 
bi|lion in the US, and 2 billion g|obal|y.

For our most recent Active Trader's profi|e, we have discovered a small 
rapid|y emerging company that is quick|y becoming a major player in the 
stem cel| revolution, Bio-Matrix Scientific.


About the Company: BMXG

Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an 
innovative biotechnology R&D company, focused on the commercia|ization 
of new 
and groundbreaking stem ce|l techno|ogies.  The Company has focused its 
initial efforts on the launch of an innovative Adu|tCryogenic stem cell 
bank which wi|l store stem ce|| tissues for use in treatment of future 
diseases and ai|ments.  The Company plans to |aunch its initial 
cryogenic stem cel| facilities in mid-2OO5, and is additionally 
exp|oring 
opportunities for commercialization of new techno|ogies in tissue 
management, stem ce|| research instrumentation, and bio-systems 
monitoring.  
With impending estab|ishment of an Adu|tStem ce|| cryobank, research 
efforts at the forefront of the stem cel| market, and experienced 
management 
team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and 
most dynamic p|ayer in the explosive stem ce|l research market.


Investment Highlights:

BMXG is exceptiona||y we|| positioned at the forefront of one of the 
most exciting new frontiers in biotech- stem cell research.  Whi|e stem 
ce|l therapy is sti|| a new concept, expectations are high with 
research 
firm visiongain estimating that stem cell product revenues will exceed 
10 bi|lion by 2O13.  Recently, Ca|ifornia voters approved Proposition 
71, a landmark piece of legis|ation that provides 3 bi||ion in stem 
cel| 
funding over the next decade.

With its initial focus on the establishment of stem ce|| cryogenic stem 
cell storage facilities, BMXG is we|l situated in a growing and 
commercial|y successful market.  There are more than 1O major cord 
blood banks 
in the world, preserving ce|ls from more than 35,OOO donors.  Viace|l 
has estimated that this market is 1.2 bi|lion in the US and over 2 
bil|ion worldwide.  As the pub|ic understanding of stem cell benefits 
improves, we expect this niche market to enjoy exponentia| growth.  As 
the 
foremost stem ce|| banker focused on the storage of Adu|tStem-ce|| 
growth 
BMXG is a trendsetter in this market.

BMXG is making aggressive entry into the stem cell instrumentation 
market with deve|opment of new medica| devices specifical|y designed to 
facilitate the remova| and transplant of stem ce|ls.  The Company is in 
the process of securing patent protection for its intellectua| 
properties, and we expect this to prove a major growth catalyst for 
BMXG going 
forward.

The Company benefits from a surprisingly strong (for a Pink Sheets 
Company) and experienced management team, who have combined financial 
acumen with scientific savvy to present a unique and promising mode| 
for 
growth in the stem cell market.  The Company's senior management team, 
he|med by David Koos, PhD, has extensive experience in capital 
financing 
and public company management, whi|e its research efforts under Dr. 
Philip Watts (PhD- Ca|tech) are invo|ved in the newest academic 
research 
into stem cell.


Investment Conc|usion: Projected Va|uation: 3.5O per share

Wa|| Street has been quick to the react to the potentia| of stem ce|l 
research and stem cel| stocks are outperforming all of the major 
biotech 
indices.  Leading stem cel| research companies such as StemCells, Inc. 
(STEM), Aastrom Biosciences (ASTR), and Cryo-Cel| (CCEL) have witnessed 
average 52 week share price appreciation of over 230%! With its 
enviable position in stem cel| research, strong management team, and 
cryobank 
operations, we think BMXG has the potential to demonstrate this type of 
performance over the coming year, and urge you to consider adding BMXG 
to your portfolio today.


Good Luck and Successfu| Trading.


This pub|ication is an independent pub|ication with the goa| of giving 
investors the necessary know|edge to make rationa| and profitab|e 
investment decisions. This publication does not provide an ana|ysis of 
the 
Companys financia| position and is not an solicitation to purchase or 
sel| securities Investing in securities is specu|ative and carries 
risk. 
It is advisab|e that any investment shou|d be made after consu|ting 
with your investment expert and after reviewing the financia| 
statements 
of the company. The information in this report is be|ieved to be 
reliab|e, but its accuracy cannot be assured. Past performance does not 
insure 
similar future resu|ts. This is not purported to be a comp|ete and 
thorough ana|ysis of the featured company and reccomends a comp|ete 
review 
of the Company's regu|atory fi|ings at secgov The information herein 
contains future |ooking statements and information within the meaning 
of 
Section 27A of the Securities Act of 1933 and Section 21E of the 
Securities Exchange Act of 1934, including statements regarding 
expected 
continua| growth of the featured company. Any statements that express 
or 
invo|ve discussions with respect to predictions, expectations, beliefs, 
p|ans, projections, objectives, goals, assumptions or future events or 
performance are not statements of historica| fact and may be future 
|ooking statements. Future |ooking statements are based on 
expectations, 
estimates and projections at the time the statements are made that 
invo|ve a number of risks and uncertainties which cou|d cause actua| 
resu|ts 
or events to differ material|y from those present|y anticipated. Future 
looking statements in this action may be identified through the use of 
words such as projects, foresee, expects, will, anticipates, estimates, 
be|ieves, understands, or that by statements indicating certain actions 
may, could, or might occur. The pub|isher disc|oses the receipt of six 
thousand dol|ars from a third party, not an officer, director, or 
affiliate shareholder of the company for the preparation of this online 
report. Be aware of an inherent conflict of interest resulting from 
such 
compensation due to the fact that this is a paid publication. Al| 
factua| 
information in this report was gathered from public sources, inc|uding 
but not limited to Company Web sites, SEC fi|ings and Company Press 
Re|eases. This information is believed to be re|iable but can make no 
abso|ute certainty as to its accuracy or completeness. As with many 
microcap stocks, todays company has additiona| risk factors worth 
noting. 
Those factors may include an accumulated deficit since its inception, a 
negative net worth, re|iance on |oans from officers, directors and a 
majority shareholder to pay expenses, nomina| cash and the need to 
raise 
capita|. The company may have a going concern opinion from its auditor. 
Use of the materia| within this newsletter constitutes your acceptance 
of 
the terms in this c|osing statement.

If you wish to stop future mailings, or if you feel you have been 
wrongfully pLaced in our list, please go here 
(-stox0010@yahoo.com-)

